Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977642 | 0.88 | KLKB1 (0.39) | DGAT1KLKB1NPC1MAPTCYP11B1 | |
| SCHEMBL23421629 | 0.87 | NPC1 (0.40) | DGAT1KLKB1NPC1MAPTCYP11B1 | |
| SCHEMBL19924689 | 0.86 | CYP11B1 (0.47) | DGAT1KLKB1NPC1MAPTCYP11B1 | |
| SCHEMBL16397034 | 0.83 | CYP11B2 (0.43) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL1858220 | 0.80 | DGAT1 (0.40) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL14858057 | 0.79 | MEN1 (0.35) | DGAT1KLKB1NPC1MAPTCYP11B1 | |
| SCHEMBL8543053 | 0.78 | NPC1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL31377235 | 0.77 | DGAT1 (0.36) | DGAT1KLKB1NPC1MAPTCYP11B1 | |
| SCHEMBL5767723 | 0.76 | CYP11B1 (0.38) | DGAT1NPC1CYP11B1CYP11B2 | |
| SCHEMBL1395957 | 0.75 | ALDH1A1 (0.35) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | DGAT1 4718/4885KLKB1 3721/4885NPC1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.